Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 9/20 | 0.49 |
| ▸ | HEXA | P06865 | 1/20 | 0.48 |
| ▸ | HEXB | P07686 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407389 | 0.78 | PDE10A (0.71) | PDE10AHTR1A | |
| SCHEMBL24943586 | 0.78 | NCF1 (0.52) | PDE10A | |
| SCHEMBL18669186 | 0.77 | PDE10A (0.61) | PDE10AHTR1A | |
| SCHEMBL25443453 | 0.76 | MAOB (0.73) | MAOBACHEHEXAHEXBHTR1A | |
| SCHEMBL10951154 | 0.76 | MAOB (1.00) | MAOBACHE | |
| SCHEMBL21066763 | 0.75 | NCF1 (0.46) | PDE10A | |
| SCHEMBL4871016 | 0.74 | MAOB (0.58) | MAOBACHE | |
| SCHEMBL4870435 | 0.74 | CARM1 (0.51) | PDE10A | |
| SCHEMBL5049345 | 0.74 | MAOB (0.78) | MAOBACHE | |
| SCHEMBL21066731 | 0.73 | GPBAR1 (0.48) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| EP-1618119-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | MAOB 1325/4885PDE10A 1118/4885ACHE 4144/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | MAOB 3279/4885PDE10A 1947/4885ACHE 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.